Astellas Pharma is a leading Japanese pharmaceutical company focused on oncology, transplantation, and urology therapeutic areas. The company markets several globally recognized prescription medicines and has built a substantial international revenue base, with the United States representing its largest market. Astellas has been actively investing in next-generation modalities including gene therapy and cell therapy as part of its long-term research strategy.

For international investors, Astellas Pharma is a Japan-based global pharmaceutical company with a focused portfolio in oncology, transplantation, and urology. The company generates the majority of its revenues from international markets, particularly the United States and Europe, where its key products hold established market positions. Astellas' ongoing investment in next-generation oncology therapies, including cell therapies and targeted treatments, represents its principal long-term growth strategy.